- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 14, 2022
Emerging Company Profile
Lucy: mitochondrial solutions to CNS diseases
Company’s first indications are Parkinson’s disease, Rett syndrome
BioCentury | Nov 10, 2022
Deals
Nov. 9 Quick Takes: Royalty deal brings Arrowhead $250M as partner Amgen preps Phase III
Plus: Bankruptcy ‘increasingly probable’ for Clovis, and updates from Veru, SOBI, GSK and more
BioCentury | Nov 21, 2020
Product Development
Nov. 20 Quick Takes: uniQure hemophilia therapy hits pivotal endpoint; plus data from Gilead in HIV, Aivita in GBM and a setback for Poxel
uniQure hemophilia therapy hits co-primary Phase III endpointuniQure N.V. (NASDAQ:QURE) said gene therapy etranacogene dezaparvovec met one primary endpoint of the Phase III HOPE-B trial to treat
BioCentury | Jun 26, 2019
Clinical News
June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more
BioCentury | Apr 12, 2019
Clinical News
Poxel's imeglimin meets in first Japanese Phase III for Type II diabetes
Items per page:
1 - 10 of 65